Hostname: page-component-7dd5485656-dk7s8 Total loading time: 0 Render date: 2025-10-31T12:42:27.732Z Has data issue: false hasContentIssue false
  • English
  • Français

Transdiagnostic use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy to treat obsessive–compulsive disorder (OCD): commentary, Brakoulias and Rossell

Published online by Cambridge University Press:  21 July 2025

Vlasios Brakoulias Open the ORCID record for Vlasios Brakoulias [Opens in a new window]  and
Susan L. Rossell
Vlasios Brakoulias*
Affiliation:
Sydney Medical School – Westmead, Specialty of Psychiatry, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Susan L. Rossell
Affiliation:
School of Health Sciences, Swinbourne University of Technology, Hawthorn, Victoria, Australia
*
Correspondence: Vlasios Brakoulias. Email: vlasios.brakoulias@sydney.edu.au
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Obsessive–compulsive disordertreatmentspsychedelicspsychological treatments

Information

Type
Commentary
Information
The British Journal of Psychiatry , Volume 227 , Issue 3 , September 2025 , pp. 641 - 642
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Saade, Z, Keuroghlian, A. Transdiagnostic use of 3,4 methylenedioxymethamphetamine (MDMA)-assisted therapy to treat obsessive–compulsive disorder (OCD). Br J Psychiatry [Epub ahead of print] 26 Feb 2025. Available from: doi: 10.1192/bjp.2024.277.CrossRefGoogle Scholar
Ong, CW, Clyde, JW, Bluett, EJ, Levin, ME, Twohig, MP. Dropout rates in exposure with response prevention for obsessive-compulsive disorder: what do the data really say? J Anxiety Disord 2016; 40: 8–17.CrossRefGoogle Scholar
Moreno, FA, Wiegand, CB, Taitano, EK, Delgado, PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 1735–40.CrossRefGoogle ScholarPubMed
Fitzgerald, P, Bailey, N, Fitzgibbon, B, Perera, M. Developing Optimal Psychedelic Assisted Psychotherapy for Obsessive-Compulsive Disorder. Australian National University, 2025 (https://medicine-psychology.anu.edu.au/research/research-projects/opt-pap-developing-optimal-psychedelic-assisted-psychotherapy-obsessive [accessed 6 Jan 2025]).Google Scholar
Rodriguez, C. MDMA-Assisted CBT for OCD, Trial ID: NCT05783817. Stanford University School of Medicine, n.d. (https://clinicaltrials.stanford.edu/trials/m/NCT05783817.html [accessed 6 Jan 2025]).Google Scholar
Yaden, D. Psilocybin Study for Obsessive-Compulsive Disorder, IRB00284207. Johns Hopkins University, n.d. (https://hopkinspsychedelic.org/ocd-study [accessed 6 Jan 2025]).Google Scholar
Ehrmann, K, Allen, JJ, Moreno, FA. Psilocybin for the treatment of obsessive–compulsive disorders. Disrupt Psychopharmacol 2021; 17: 247–59.CrossRefGoogle Scholar
Ruscio, AM, Stein, DJ, Chiu, WT, Kessler, RC. The epidemiology of obsessive–compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15: 53–63.CrossRefGoogle ScholarPubMed
Sisti, D. Ethics in psychedelic science: promises and responsibilities. J Clin Psychopharmacol 2025; 45: 1–3.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.